# Understanding the Role and Application of Lanreotide 120 mg
When exploring long-acting therapeutic peptides and synthetic analogues, understanding the specific mechanisms behind compounds like lanreotide 120 mg is essential. As someone who follows advancements in peptide research and biotechnology, I have closely observed how synthetic octapeptides are utilized in various research settings to mimic the inhibitory effects of natural hormones.
Lanreotide is a synthetic somatostatin analogue. In its structural form, it functions similarly to the naturally occurring hormone somatostatin, which helps regulate endocrine activity. The 120 mg dosage represents a high-concentration, prolonged-release formulation, typically supplied in a pre-fill Somatuline® Depot (lanreotide) | Official Patient Information Site ed, deep subcutaneo CIP_Lanreotide BCG_Brochure _D-option1_v6.1_13Jun24 us syringe. This delivery method is designed to provide stable exposure over an extended period.
When researching what is lanreotide used for, one discovers that its primary utility in clinical literature is tied to the management of physiological conditions involving growth hormonal regulation, specifically acromegaly, as well as the management of neuroendocrine tumors.
Essential Specifications and Administration
The lanreotide brand name most frequently encountered in scientific literature and clinical databases is Somatuline Depot (also known as Somatuline Autogel in various international markets). However, as patent protections have evolved, a lanreotide generic name has also entered the landscape, providing alternatives in the peptide market.
Regarding how frequently is lanreotide administered, the 120 mg dose is typically categorized under a sustained-release protocol. The frequency is determined by specific experimental or clinical parameters, often administered once every four weeks to maintain steady-state levels.
Important Considerations: Safety and Monitoring
For those tracking the safety profile of this compound, understanding lanreotide side effects is critical. Common observations in clinical studies often include localized injection site reactions, such as tenderness or nodules, and transient gastrointestinal variations. These are standard considerations for individuals reviewing the safety data of somatostatin analogues.
Furthermore, lanreotide warnings emphasize the need for careful handling and proper storage. Because it is a sensitive peptide complex, strict adherence to temperature-controlled storage environments is required to maintain the molecular integrity of the substance.
If you are researching what is lanreotide injection specifically, it is categorized as a deep subcutaneous administration. Practitioners and researchers loo Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide k closely at lanreotide indications to ensure the compound align Apr 22, 2021 · The FDA approval was based on a New Drug Application (NDA) submitted under the 505 (b) (2) filing pathway. … s with the specific research objective or therapeutic target. Understanding these parameters is a fundamental part of evaluating how these long-acting analogues operate in a controlled capacity.
Integrating Research Perspectives
The shift toward using generic analogues and the approval of diverse delivery s IPSTYL SC SIR 120MG - Foglietto Illustrativo ystems have made the study of this peptide more accessible. Whether analyzing the phase II CLARINET data or observing how regulatory bodies establish, for example, lanreotide indications for specific tumor management, the focus remains on the peptide’s ability to bind to somatostatin receptors with high affinity.
By maintaining awareness of these technical details, enthusiasts of peptide science can better appreciate the complex pharmacology behind compounds like lanreotide 120 mg. Always en Somatuline® Depot (lanreotide) | Official HCP Site sure that any engagement with such substances is conducted within the scope of established, verifiable sa Pharmac to Fund Lanreotide from March 2025 – Acromegaly NZ fety and regulatory frameworks, keeping in mind that the primary value of this research lies in its precision and molecular specificity.
# Understanding the Role and Application of Lanreotide 120 mg
When exploring long-acting therapeutic peptides and synthetic analogues, understanding the specific mechanisms behind compounds like lanreotide 120 mg is essential. As someone who follows advancements in peptide research and biotechnology, I have closely observed how synthetic octapeptides are utilized in various research settings to mimic the inhibitory effects of natural hormones.
Lanreotide is a synthetic somatostatin analogue. In its structural form, it functions similarly to the naturally occurring hormone somatostatin, which helps regulate endocrine activity. The 120 mg dosage represents a high-concentration, prolonged-release formulation, typically supplied in a pre-fill Somatuline® Depot (lanreotide) | Official Patient Information Site ed, deep subcutaneo CIP_Lanreotide BCG_Brochure _D-option1_v6.1_13Jun24 us syringe. This delivery method is designed to provide stable exposure over an extended period.
When researching what is lanreotide used for, one discovers that its primary utility in clinical literature is tied to the management of physiological conditions involving growth hormonal regulation, specifically acromegaly, as well as the management of neuroendocrine tumors.
Essential Specifications and Administration
The lanreotide brand name most frequently encountered in scientific literature and clinical databases is Somatuline Depot (also known as Somatuline Autogel in various international markets). However, as patent protections have evolved, a lanreotide generic name has also entered the landscape, providing alternatives in the peptide market.
Regarding how frequently is lanreotide administered, the 120 mg dose is typically categorized under a sustained-release protocol. The frequency is determined by specific experimental or clinical parameters, often administered once every four weeks to maintain steady-state levels.
Important Considerations: Safety and Monitoring
For those tracking the safety profile of this compound, understanding lanreotide side effects is critical. Common observations in clinical studies often include localized injection site reactions, such as tenderness or nodules, and transient gastrointestinal variations. These are standard considerations for individuals reviewing the safety data of somatostatin analogues.
Furthermore, lanreotide warnings emphasize the need for careful handling and proper storage. Because it is a sensitive peptide complex, strict adherence to temperature-controlled storage environments is required to maintain the molecular integrity of the substance.
If you are researching what is lanreotide injection specifically, it is categorized as a deep subcutaneous administration. Practitioners and researchers loo Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide k closely at lanreotide indications to ensure the compound align Apr 22, 2021 · The FDA approval was based on a New Drug Application (NDA) submitted under the 505 (b) (2) filing pathway. … s with the specific research objective or therapeutic target. Understanding these parameters is a fundamental part of evaluating how these long-acting analogues operate in a controlled capacity.
Integrating Research Perspectives
The shift toward using generic analogues and the approval of diverse delivery s IPSTYL SC SIR 120MG - Foglietto Illustrativo ystems have made the study of this peptide more accessible. Whether analyzing the phase II CLARINET data or observing how regulatory bodies establish, for example, lanreotide indications for specific tumor management, the focus remains on the peptide’s ability to bind to somatostatin receptors with high affinity.
By maintaining awareness of these technical details, enthusiasts of peptide science can better appreciate the complex pharmacology behind compounds like lanreotide 120 mg. Always en Somatuline® Depot (lanreotide) | Official HCP Site sure that any engagement with such substances is conducted within the scope of established, verifiable sa Pharmac to Fund Lanreotide from March 2025 – Acromegaly NZ fety and regulatory frameworks, keeping in mind that the primary value of this research lies in its precision and molecular specificity.